Cognitive performances and DAT imaging in early Parkinson's disease with mild cognitive impairment: A preliminary study

Acta Neurologica Scandinavica

Volumn 131, Issue 5, 2015, Pages 275-281

  Pellecchia, M T ^a   Picillo, M ^b   Santangelo, G ^c,d   Longo, K ^d   Moccia, M ^b   Erro, R ^b   Amboni, M ^d   Vitale, C ^d,e   Vicidomini, C ^f   Salvatore, M ^b   Barone, P ^b   Pappata S ^f  

^a UNIVERSITY OF SALERNO   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c SECOND UNIVERSITY OF NAPLES   (Italy)

^d IDC Hermitage Capodimonte   (Italy)

^e UNIVERSITY OF NAPLES PARTHENOPE   (Italy)

^f CNR   (Italy)

Author keywords

SPECT; Cognition; Dopamine transporter; Early Parkinson's disease; Mild cognitive impairment

Indexed keywords

IOFLUPANE I 123; 2-CARBOMETHOXY-8-(3-FLUOROPROPYL)-3-(4-IODOPHENYL)TROPANE; DOPAMINE TRANSPORTER; TROPANE DERIVATIVE;

ADULT; ARTICLE; ATTENTION; CLINICAL ARTICLE; COGNITION; CONTROLLED STUDY; DISEASE DURATION; DISEASE SEVERITY; DSM-IV; EXECUTIVE FUNCTION; FEMALE; HOSPITAL ANXIETY AND DEPRESSION SCALE; HUMAN; LEARNING; MALE; MEMORY; MILD COGNITIVE IMPAIRMENT; PARKINSON DISEASE; PSYCHOLOGIC TEST; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SPECT SCANNER; STROOP TEST; UNIFIED PARKINSON DISEASE RATING SCALE; WORKING MEMORY; AGED; COMPLICATION; CORPUS STRIATUM; DIAGNOSTIC USE; METABOLISM; MIDDLE AGED; PROCEDURES; PSYCHOLOGICAL RATING SCALE; SCINTISCANNING;

AGED; CORPUS STRIATUM; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FEMALE; HUMANS; MALE; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; PARKINSON DISEASE; PSYCHIATRIC STATUS RATING SCALES; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TROPANES;

EID: 84926355335     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/ane.12365     Document Type: Article

References (35)

1. Williams-Gray CH, Foltynie T, Brayne CEG et al. Evolution of cognitive dysfunction in an incident Parkinson's disease cohort. Brain 2007;130:1787-98.
2. Elgh E, Domellof M, Linder J et al. Cognitive function in early Parkinson's disease: a population-based study. Eur J Neurol 2009;16:1278-84.
3. Muslimovic D, Post B, Speelman JD, Schmand B. Cognitive profile of patients with newly diagnosed Parkinson's disease. Neurology 2005;65:1239-45.
4. Aarsland D, Bronnick K, Williams-Gray C et al. Mild cognitive impairment in Parkinson disease: a multicenter pooled analysis. Neurology 2010;5:1062-9.
5. Pfeiffer HC, Løkkegaard A, Zoetmulder M et al. Cognitive impairment in early-stage non-demented Parkinson's disease patients. Acta Neurol Scand 2014;129:307-18.
6. Pavese N. PET studies in Parkinson's disease motor and cognitive dysfunction. Parkinsonism Relat Disord 2012;18:S96-9.
7. Pappatà S, Salvatore E, Postiglione A. In vivo imaging of neurotransmission and brain receptors in dementia. J Neuroimaging 2008;18:111-24.
8. Fitzpatrick T, Mattis P, Eidelberg D. Functional imaging of cognitive impairment in Parkinson's disease. Clin EEG Neurosci 2010;41:119-26.
9. Muller U, Wachter T, Barthel H et al. Striatal [123I] b-CIT SPECT and prefrontal cognitive functions in Parkinson's disease. J Neural Transm 2000;107:303-19.
10. Duchesne N, Soucy J-P, Masson H et al. Cognitive deficits and striatal dopaminergic denervation in Parkinson's disease: a single photon emission computed tomography study using 123Iodine-b-CIT in patients ON and OFF levodopa. Clin Neuropharmacol 2002;25:216-24.
11. Cropley VL, Fujita M, Bara-Jimenez W et al. Pre and post synaptic dopamine imaging and its relation with frontostriatal cognitive function in Parkinson's disease: PET studies with [11C]NNC 112 and [18F]FDOPA. Psychiatry Res 2008;163:171-82.
12. Weder BJ, Leenders KL, Vontobel P et al. Impaired somatosensory discrimination of shape in Parkinson's disease: association with caudate nucleus dopaminergic function. Hum Brain Mapp 1999;8:1-12.
13. Mariè RM, Barre L, Dupuy B et al. Relationships between striatal dopamine denervation and frontal executive tests in Parkinson's disease. Neurosci Lett 1999;260:77-80.
14. Rinne JO, Portin R, Ruottinen H et al. Cognitive impairment and the brain dopaminergic system in Parkinson disease: [18F]fluorodopa positron emission tomographic study. Arch Neurol 2000;57:470-5.
15. Jokinen P, Bruck A, Aalto S et al. Impaired cognitive performance in Parkinson's disease is related to caudate dopaminergic hypofunction and hippocampal atrophy. Parkinsonism Relat Disord 2009;15:88-93.
16. Nobili F, Campus C, Arnaldi D et al. Cognitive-nigrostriatal relationships in de novo, drug-naïve Parkinson's disease patients: a [I-123]FP-CIT study. Mov Disord 2010;25:35-43.
17. Holthoff VA, Vieregge P, Kessler J et al. Discordant twins with Parkinson's disease: positron emission tomography and early signs of impaired cognitive circuits. Ann Neurol 1994;6:176-82.
18. Emre M, Aarsland D, Brown R et al. Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord 2007;22:1689-707.
19. Litvan I, Goldman JG, Troster AI et al. Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force Guidelines. Mov Disord 2012;27:349-56.
20. Booij J, Hemelaar TG, Speelman JD, et al. One-day protocol for imaging of the nigrostriatal dopaminergic pathway in Parkinson's disease by [123]FPCIT SPECT. J Nucl Med 1999;40:753-61.
21. Varrone A, Pellecchia MT, Amboni M, et al. Imaging of dopaminergic dysfunction with 123I-FP-CIT SPECT in early-onset parkin disease. Neurology 2004;63:2097-103.
22. Polito C, Berti V, Ramat S, et al. Interaction of caudate dopamine depletion and brain metabolic changes with cognitive dysfunction in early Parkinson's disease. Neurobiol Aging 2012;33:206.e29-39.
23. Kehagia AA, Barker RA, Robbins TW. Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson's disease. Lancet Neurol 2010;9:1200-13.
24. Shen LH, Liao MH, Tseng YC. Recent advances in imaging of dopaminergic neurons for evaluation of neuropsychiatric disorders. J Biomed Biotechnol 2012;2012:259349.
25. Yamanaka T, Ishii F, Umemura A, et al. Temporary deterioration of executive function after subthalamic deep brain stimulation in Parkinson's disease. Clin Neurol Neurosurg 2012;114:347-51.
26. Paschali A, Messinis L, Kargiotis O, et al. SPECT neuroimaging and neuropsychological functions in different stages of Parkinson's disease. Eur J Nucl Med Mol Imaging 2010;37:1128-40.
27. Brück A, Portin R, Lindell A, et al. Positron emission tomography shows that impaired frontal lobe functioning in Parkinson's disease is related to dopaminergic hypofunction in the caudate nucleus. Neurosci Lett 2001;311:81-4.
28. van Beilen M, Portman AT, Kiers HAL, et al. Striatal FDOPA uptake and cognition in advanced non-demented Parkinson's disease: a clinical and FDOPA-PET study. Parkinsonism Relat Disord 2008;14:224-8.
29. Lozza C, Baron JC, Eidelberg D, et al. Executive processes in Parkinson's disease: FDG-PET and network analysis. Hum Brain Mapp 2004;22:236-45.
30. Lebedev AV, Westman E, Simmons A, et al. Large-scale resting state network correlates of cognitive impairment in Parkinson's disease and related dopaminergic deficits. Front Syst Neurosci 2014;8:45.
31. Ekman U, Eriksson J, Forsgren L, et al. Functional brain activity and presynaptic dopamine uptake in patients with Parkinson's disease and mild cognitive impairment: a cross-sectional study. Lancet Neurol 2012;11:679-87.
32. Narayanan NS, Rodnitzky RL, Uc EY. Prefrontal dopamine signaling and cognitive symptoms of Parkinson's Disease. Rev Neurosci 2013;24:267-78.
33. Christopher L, Marras C, Duff-Canning S, et al. Combined insular and striatal dopamine dysfunction are associated with executive deficits in Parkinson's disease with mild cognitive impairment. Brain 2014;137:565-75.
34. Petrou M, Bohnen NI, Muller ML, et al. Aβ-amyloid deposition in patients with Parkinson disease at risk for development of dementia. Neurology 2012;79:1161-7.
35. Gomperts SN, Locascio JJ, Rents D, et al. Amyloid is linked to cognitive decline in patients with Parkinson disease without dementia. Neurology 2013;80:85-91.